
Yahoo · 15 de sept de 2026
AI safety warnings sent tech stocks lower Monday, pushing investors into J&J, Eli Lilly, Kimberly-Clark, and Costco.
Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Últimos 203 días · 12/11/25 — 14/09/26
+46.60%
Precio
$ 28.100
Var. %
-1,05%
Volumen operado
4.968
Precio JNJ
US$ 264,60
Teórico (precio / ratio)
JNJ ÷ 15
US$ 17,64
Sí, existe el CEDEAR de JNJ (Johnson & Johnson) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es JNJ.
El ticker del CEDEAR de Johnson & Johnson en Argentina es JNJ. La acción subyacente cotiza en NYSE con el símbolo JNJ.
El CEDEAR JNJ tiene un ratio de 15:1. Eso significa que 15 CEDEARs equivalen a 1 acción de JNJ.
El CEDEAR JNJ cotiza hoy a $ 28.100 en pesos argentinos, con una variación diaria de -1,05%.
La acción subyacente JNJ (Johnson & Johnson) cotiza a US$ 264,60 en su mercado de origen (NYSE).

Yahoo · 15 de sept de 2026
AI safety warnings sent tech stocks lower Monday, pushing investors into J&J, Eli Lilly, Kimberly-Clark, and Costco.

Yahoo · 15 de sept de 2026
J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.

Yahoo · 15 de sept de 2026
Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 2b COPERNICUS study evaluating how subcutaneous RYBREVANT FASPRO (amivantamab and hyalur…
Precio de cierre en pesos argentinos. Fuente: data912.
Cotización
US$ 18,41
vs teórico
+4,37%
Cotización MEP implícita
$ 1.526,34
Cotización
US$ 17,51
vs teórico
-0,74%
Cotización Cable implícita
$ 1.604,8
El precio teórico del CEDEAR JNJ se calcula dividiendo el precio de JNJ por el ratio (15). Hoy resulta en US$ 17,64.
En BYMA podés operar JNJ en pesos, JNJD en dólar MEP y JNJC en dólar cable. Cada modalidad refleja un tipo de cambio distinto.
En esta página encontrás un gráfico con el precio histórico del CEDEAR JNJ en pesos argentinos, con datos de data912.

Yahoo · 14 de sept de 2026
Contineum said that Johnson & Johnson’s (JNJ) mid-stage trial of JNJ-5120, also known as PIPE-307, failed to meet its main goal in major depressive disorder.

Yahoo · 14 de sept de 2026
Eli Lilly (LLY) trades near $1,120, about 13% below the high it set in August, and the question is whether to step in. The stock's record after sharp falls is c…

Yahoo · 14 de sept de 2026
Pfizer (PFE) throws off free cash worth 7.0% of its market value a year, against 4.4% for the median S&P 500 company. Everything turns on whether the cash holds…

Yahoo · 14 de sept de 2026
Johnson & Johnson (NYSE:JNJ) executives said the company remains on track to grow through biosimilar competition for STELARA and expects its portfolio of medici…

Yahoo · 14 de sept de 2026
These alleged talks come as J&J considers what direction to take DePuy Synthes in as it spins out from the wider business.
Noticias vía Finnhub